Mitochondrial metabolism blockade nanoadjuvant reversed immune-resistance microenvironment to sensitize albumin-bound paclitaxel-based chemo-immunotherapy-Reference-Cited by-同舟云学术

Mitochondrial metabolism blockade nanoadjuvant reversed immune-resistance microenvironment to sensitize albumin-bound paclitaxel-based chemo-immunotherapy

Published:2024-09 Issue:9 Volume:14 Page:4087-4101
ISSN:2211-3835
Container-title:Acta Pharmaceutica Sinica B
language:en
Short-container-title:Acta Pharmaceutica Sinica B

Author:

Zhou Zaigang^ORCID,Luo Wenjuan,Zheng Chunjuan,Wang Haoxiang,Hu Rui,Deng Hui,Shen Jianliang^ORCID

Publisher

Elsevier BV

Reference55 articles.

1. Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J Clin,2021

2. Multi-responsive nanotheranostics with enhanced tumor penetration and oxygen self-producing capacities for multimodal synergistic cancer therapy;Gou;Acta Pharm Sin B,2022

3. Complete response to avelumab and IL-15 superagonist N-803 with Abraxane in merkel cell carcinoma: a case study;Drusbosky;J Immunother Cancer,2020

4. Comparing neoadjuvant Nab-paclitaxel vs paclitaxel both followed by anthracycline regimens in women with ERBB2/HER2-negative breast cancer-the evaluating treatment with neoadjuvant Abraxane (ETNA) trial: a randomized phase 3 clinical trial;Gianni;JAMA Oncol,2018

5. Taxanes trigger cancer cell killing in vivo by inducing non-canonical T cell cytotoxicity;Vennin;Cancer Cell,2023

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Quercetin and doxorubicin co-delivery using β-cyclodextrin nanocarrier overcomes multi-drug resistance in cancer cells via targeting Akt/NF-κB/ABCB1 signaling pathway;Emergent Materials;2024-09-04